T

Thalia Therapeutics

HealthUnited Kingdom

Thalia Therapeutics is a UK-based biotechnology company specializing in RNA-based medical solutions. The company has raised €3.1 million to accelerate its clinical-stage oncology and RNA-based pipeline, including the acquisition of Sanmirna Therapeutics, which brings a microRNA therapeutic candidate into its portfolio.

🏆 Featured in Datapile’s Q2 2026 UK Funding Report

Read the Q2 2026 UK report →
Add this badge to your site
<a href="https://datapile.co/reports/q2-2026-uk-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q2 2026 UK Funding Report</a>

Funding history

  1. $3.3M2026-06-28
    Source: news.google.com

Founder

D
Dr. David Solomon
CEO

Investors in Thalia Therapeutics

Backers from this company's tracked funding rounds.

  • Premier Miton

More Health companies

Recently funded startups in the same category.

Related on Datapile